...
biib-img

Biogen Inc, Common Stock

BIIB

NSQ

$146.79

-$3.85

(-2.56%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$21.95B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
13.6203
Volume info-icon
This is the total number of shares traded during the most recent trading day.
1.45M
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
-0.06
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$148.6 L
$268.3 H
$146.79

About Biogen Inc, Common Stock

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameBIIBSectorS&P500
1-Week Return-6.78%-2.06%-0.55%
1-Month Return-7.06%-1.92%2.72%
3-Month Return-25.71%-10.4%7.66%
6-Month Return-34.37%-4.6%10.15%
1-Year Return-41.36%4.06%27.53%
3-Year Return-38.05%1.94%32.31%
5-Year Return-50.51%36.48%89.2%
10-Year Return-58.5%97.46%194.59%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue14.38B13.44B10.98B10.17B9.84B[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":93.51,"profit":true},{"date":"2021-12-31","value":76.38,"profit":true},{"date":"2022-12-31","value":70.76,"profit":true},{"date":"2023-12-31","value":68.41,"profit":true}]
Cost of Revenue1.96B1.81B2.11B2.28B2.53B[{"date":"2019-12-31","value":77.18,"profit":true},{"date":"2020-12-31","value":71.26,"profit":true},{"date":"2021-12-31","value":83.28,"profit":true},{"date":"2022-12-31","value":89.93,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Profit12.42B11.64B8.87B7.90B7.30B[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":93.7,"profit":true},{"date":"2021-12-31","value":71.42,"profit":true},{"date":"2022-12-31","value":63.55,"profit":true},{"date":"2023-12-31","value":58.78,"profit":true}]
Gross Margin86.40%86.57%80.79%77.61%74.24%[{"date":"2019-12-31","value":99.8,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":93.32,"profit":true},{"date":"2022-12-31","value":89.64,"profit":true},{"date":"2023-12-31","value":85.76,"profit":true}]
Operating Expenses5.39B7.19B6.06B4.99B6.01B[{"date":"2019-12-31","value":74.89,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":84.3,"profit":true},{"date":"2022-12-31","value":69.42,"profit":true},{"date":"2023-12-31","value":83.49,"profit":true}]
Operating Income7.04B4.55B2.84B2.32B2.10B[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":64.61,"profit":true},{"date":"2021-12-31","value":40.34,"profit":true},{"date":"2022-12-31","value":32.95,"profit":true},{"date":"2023-12-31","value":29.78,"profit":true}]
Total Non-Operating Income/Expense15.90M316.90M(1.34B)174.10M(770.90M)[{"date":"2019-12-31","value":5.02,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-422.25,"profit":false},{"date":"2022-12-31","value":54.94,"profit":true},{"date":"2023-12-31","value":-243.26,"profit":false}]
Pre-Tax Income7.13B5.05B1.75B3.59B1.30B[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":70.83,"profit":true},{"date":"2021-12-31","value":24.49,"profit":true},{"date":"2022-12-31","value":50.4,"profit":true},{"date":"2023-12-31","value":18.2,"profit":true}]
Income Taxes1.16B992.30M52.50M632.80M135.30M[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":85.69,"profit":true},{"date":"2021-12-31","value":4.53,"profit":true},{"date":"2022-12-31","value":54.65,"profit":true},{"date":"2023-12-31","value":11.68,"profit":true}]
Income After Taxes5.97B4.06B1.69B2.96B1.16B[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":67.95,"profit":true},{"date":"2021-12-31","value":28.36,"profit":true},{"date":"2022-12-31","value":49.58,"profit":true},{"date":"2023-12-31","value":19.46,"profit":true}]
Income From Continuous Operations5.97B4.06B1.69B2.96B1.16B[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":67.95,"profit":true},{"date":"2021-12-31","value":28.36,"profit":true},{"date":"2022-12-31","value":49.63,"profit":true},{"date":"2023-12-31","value":19.46,"profit":true}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income5.89B4.00B1.56B3.05B1.16B[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":67.94,"profit":true},{"date":"2021-12-31","value":26.43,"profit":true},{"date":"2022-12-31","value":51.74,"profit":true},{"date":"2023-12-31","value":19.72,"profit":true}]
EPS (Diluted)33.6432.8219.1818.4515.08[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":97.56,"profit":true},{"date":"2021-12-31","value":57.02,"profit":true},{"date":"2022-12-31","value":54.85,"profit":true},{"date":"2023-12-31","value":44.83,"profit":true}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

BIIB
Cash Ratio 0.31
Current Ratio 1.26
Quick Ratio 0.80

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

BIIB
ROA (LTM) 4.99%
ROE (LTM) 10.47%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

BIIB
Debt Ratio Lower is generally better. Negative is bad. 0.42
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.58

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

BIIB
Trailing PE 13.62
Forward PE 8.86
P/S (TTM) 2.28
P/B 1.34
Price/FCF 27
EV/R 2.80
EV/Ebitda 9.62
PEG 6.24

FAQs

What is Biogen Inc share price today?

Biogen Inc (BIIB) share price today is $146.79

Can Indians buy Biogen Inc shares?

Yes, Indians can buy shares of Biogen Inc (BIIB) on Vested. To buy Biogen Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in BIIB stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Biogen Inc be purchased?

Yes, you can purchase fractional shares of Biogen Inc (BIIB) via the Vested app. You can start investing in Biogen Inc (BIIB) with a minimum investment of $1.

How to invest in Biogen Inc shares from India?

You can invest in shares of Biogen Inc (BIIB) via Vested in three simple steps:

  • Click on Sign Up or Invest in BIIB stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Biogen Inc shares
What is Biogen Inc 52-week high and low stock price?

The 52-week high price of Biogen Inc (BIIB) is $268.3. The 52-week low price of Biogen Inc (BIIB) is $148.6.

What is Biogen Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Biogen Inc (BIIB) is 13.6203

What is Biogen Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Biogen Inc (BIIB) is 1.34

What is Biogen Inc dividend yield?

The dividend yield of Biogen Inc (BIIB) is 0.00%

What is the Market Cap of Biogen Inc?

The market capitalization of Biogen Inc (BIIB) is $21.95B

What is Biogen Inc’s stock symbol?

The stock symbol (or ticker) of Biogen Inc is BIIB

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top